The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
Open accessAbstract
Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in containing the global tuberculosis epidemic. Mycobacterium tuberculosis is intrinsically resistant to many antibiotics, limiting the number of compounds available for treatment. This intrinsic resistance is due to a number of mechanisms including a thick, waxy, hydrophobic cell envelope and the presence of drug degrading and modifying enzymes. Resistance to the drugs which are active against M. tuberculosis is, in the absence of horizontally transferred resistance determinants, conferred by chromosomal mutations. These chromosomal mutations may confer drug resistance via modification or overexpression of the drug target, as well as by prevention of prodrug activation. Drug resistance mutations may have pleiotropic effects leading to a reduction in the bacterium's fitness, quantifiable e.g. by a reduction in the in vitro growth rate. Secondary so-called compensatory mutations, not involved in conferring resistance, can ameliorate the fitness cost by interacting epistatically with the resistance mutation. Although the genetic diversity of M. tuberculosis is low compared to other pathogenic bacteria, the strain genetic background has been demonstrated to influence multiple aspects in the evolution of drug resistance. The rate of resistance evolution and the fitness costs of drug resistance mutations may vary as a function of the genetic background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847 · cited 2×
“A further peculiarity ofM. tuberculosis is the apparent absence of ongoing horizontal gene transfer (Cole et al. 1998; Gagneux and Small 2007; Bolotin and Hershberg 2015).”
BackgroundMutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
Brennan, P. J., & Nikaido, H. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000333 · Cited by 1,985
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732
Selection of Resistant Bacteria at Very Low Antibiotic Concentrations
Gullberg, E., Cao, S., Berg, O. G., Ilbäck, C., Sandegren, L., Hughes, D., & Andersson, D. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002158 · Cited by 1,654
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 2×
“rifampicin resistance determining region, confer resistance to rifampicin, by decreasing the affinity of rifampicin for target (Campbell et al. 2001).”
BackgroundinhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
Schatz, A., Bugle, E., & Waksman, S. A. (1944) · Experimental Biology and Medicine · doi:10.3181/00379727-55-14461 · Cited by 1,150
Introduction to Genetic Analysis
Suzuki, D. T., & Griffiths, A. (1976) · Cited by 1,115
An Introduction to Genetic Analysis
Teplitz, R. R. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390160109041 · Cited by 1,070
Variable host–pathogen compatibility in Mycobacterium tuberculosis
Gagneux, S., DeRiemer, K., Van, T., Kato-Maeda, M., de Jong, B. C., Narayanan, S., Nicol, M., Niemann, S., Kremer, K., Gutierrez, M. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511240103 · Cited by 971
Self-citationWalker, T. M., Ip, C. L., Harrell, R. H., Evans, J. T., Kapatai, G., Dedicoat, M. J., Eyre, D. W., Wilson, D. J., Hawkey, P. M., Crook, D. W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70277-3 · Cited by 918
Further Observations on Penicillin
Abraham, E. P., Chain, E., Fletcher, C. M., Gardner, A. D., Heatley, N. G., Jennings, M. A., & Florey, H. W. (1941) · The Lancet · doi:10.1016/s0140-6736(00)72122-2 · Cited by 821 · cited 1×
“Early studies involving penicillin demonstrated that M. tuberculosis is intrinsically resistant to this class of antibiotics (Abraham et al. 1941).”
BackgroundScorpio, A., & Zhang, Y. (1996) · Nature Medicine · doi:10.1038/nm0696-662 · Cited by 726
Gagneux, S., & Small, P. M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70108-1 · Cited by 712
Self-citationContact investigation for tuberculosis: a systematic review and meta-analysis
Fox, G. J., Barry, S. E., Britton, W. J., & Marks, G. B. (2013) · European Respiratory Journal · doi:10.1183/09031936.00070812 · Cited by 709
The fitness costs of antibiotic resistance mutations
Melnyk, A. H., Wong, A., & Kassen, R. (2015) · Evolutionary Applications · doi:10.1111/eva.12196 · Cited by 689
Tuberculosis in New York City — Turning the Tide
Frieden, T. R., Fujiwara, P. I., Washko, R. M., & Hamburg, M. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330406 · Cited by 640
The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627
Self-citationAntimicrobial agent resistance in mycobacteria: molecular genetic insights
Musser, J. M. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.496 · Cited by 621
Dheda, K., Barry, C. E., & Maartens, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00151-8 · Cited by 599
Mycobacterial cell wall: Structure and role in natural resistance to antibiotics
Jarlier, V (1994) · FEMS Microbiology Letters · doi:10.1016/0378-1097(94)90267-4 · Cited by 593
High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography
Hershberg, R., Lipatov, M., Small, P. M., Sheffer, H., Niemann, S., Homolka, S., Roach, J. C., Kremer, K., Petrov, D. A., Feldman, M. W., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060311 · Cited by 593
Self-citationComas, I., Borrell, S., Roetzer, A., Rose, G., Malla, B., Kato-Maeda, M., Galagan, J., Niemann, S., & Gagneux, S. (2012) · Nature Genetics · doi:10.1038/ng.1038 · Cited by 572
Self-citationEvolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage
Merker, M., Blin, C., Mona, S., Duforet-Frebourg, N., Lecher, S., Willery, E., Blum, M. G. B., Rüsch-Gerdes, S., Mokrousov, I., Aleksic, E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3195 · Cited by 543
Self-citationLin, P. L., Ford, C. B., Coleman, M. T., Myers, A. J., Gawande, R., Ioerger, T., Sacchettini, J., Fortune, S. M., & Flynn, J. L. (2014) · Nature Medicine · doi:10.1038/nm.3412 · Cited by 533
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K., Humbert, O., Edelstein, P. H., Cosma, C. L., & Ramakrishnan, L. (2011) · Cell · doi:10.1016/j.cell.2011.02.022 · Cited by 530
Tuberculosis Drug Resistance Mutation Database
Sandgren, A., Strong, M., Muthukrishnan, P., Weiner, B. K., Church, G. M., & Murray, M. B. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000002 · Cited by 523
Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., & Blanchard, J. S. (2009) · Science · doi:10.1126/science.1167498 · Cited by 494
Hartkoorn, R. C., Uplekar, S., & Cole, S. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00037-14 · Cited by 489
Takiff, H. E., Salazar, L., Guerrero, C., Philipp, W., Huang, W. M., Kreiswirth, B., Cole, S. T., Jacobs, W. R., & Telenti, A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.773 · Cited by 480
Evolution and transmission of drug-resistant tuberculosis in a Russian population
Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S. R., Ignatyeva, O., Kontsevaya, I., Corander, J., Bryant, J., Parkhill, J., Nejentsev, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2878 · Cited by 473
The association between sterilizing activity and drug distribution into tuberculosis lesions
Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P.-Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3937 · Cited by 461
Evolution, Population Structure, and Phylogeography of Genetically Monomorphic Bacterial Pathogens
Achtman, M. (2008) · Annual Review of Microbiology · doi:10.1146/annurev.micro.62.081307.162832 · Cited by 459
Ford, C. B., Shah, R. R., Maeda, M. K., Gagneux, S., Murray, M. B., Cohen, T., Johnston, J. C., Gardy, J., Lipsitch, M., & Fortune, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2656 · Cited by 457
Self-citationEffects of Environment on Compensatory Mutations to Ameliorate Costs of Antibiotic Resistance
Björkman, J., Nagaev, I., Berg, O. G., Hughes, D., & Andersson, D. I. (2000) · Science · doi:10.1126/science.287.5457.1479 · Cited by 452
Consequences of genomic diversity in Mycobacterium tuberculosis
Coscolla, M., & Gagneux, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.012 · Cited by 451
Self-citationFarhat, M. R., Shapiro, B. J., Kieser, K. J., Sultana, R., Jacobson, K. R., Victor, T. C., Warren, R. M., Streicher, E. M., Calver, A., Sloutsky, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2747 · Cited by 440
Self-citationFord, C. B., Lin, P. L., Chase, M. R., Shah, R. R., Iartchouk, O., Galagan, J., Mohaideen, N., Ioerger, T. R., Sacchettini, J. C., Lipsitch, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.811 · Cited by 437
Compensatory ahp C Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis
Sherman, D. R., Mdluli, K., Hickey, M. J., Arain, T. M., Morris, S. L., Barry, C. E., & Stover, C. K. (1996) · Science · doi:10.1126/science.272.5268.1641 · Cited by 436
Zhang, H., Li, D., Zhao, L., Fleming, J., Lin, N., Wang, T., Liu, Z., Li, C., Galwey, N., Deng, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2735 · Cited by 429
Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model
Lin, P. L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiosea, I., Capuano, S. V., Fuhrman, C., Klein, E., et al. (2009) · Infection and Immunity · doi:10.1128/iai.00592-09 · Cited by 425
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Dartois, V. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3200 · Cited by 388
Hazbón, M. H., Brimacombe, M., Bobadilla del Valle, M., Cavatore, M., Guerrero, M. I., Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00112-06 · Cited by 374
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity
Kaplan, G., Post, F. A., Moreira, A. L., Wainwright, H., Kreiswirth, B. N., Tanverdi, M., Mathema, B., Ramaswamy, S. V., Walther, G., Steyn, L. M., et al. (2003) · Infection and Immunity · doi:10.1128/iai.71.12.7099-7108.2003 · Cited by 350
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations
Sreevatsan, S., Stockbauer, K. E., Pan, X., Kreiswirth, B. N., Moghazeh, S. L., Jacobs, W. R., Telenti, A., & Musser, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1677 · Cited by 335
Manjunatha, U. H., Boshoff, H., Dowd, C. S., Zhang, L., Albert, T. J., Norton, J. E., Daniels, L., Dick, T., Pang, S. S., & Barry, C. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508392103 · Cited by 331
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
Bloemberg, G. V., Keller, P. M., Stucki, D., Trauner, A., Borrell, S., Latshang, T., Coscolla, M., Rothe, T., Hömke, R., Ritter, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1505196 · Cited by 331
Self-citationZaunbrecher, M. A., Sikes, R. D., Metchock, B., Shinnick, T. M., & Posey, J. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907925106 · Cited by 330
Heym, B., Alzari, P. M., Honore, N., & Cole, S. T. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02238.x · Cited by 330
History of the Development of Rifampin
Sensi, P. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s402 · Cited by 315
Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis
Dye, C., Williams, B. G., Espinal, M. A., & Raviglione, M. C. (2002) · Science · doi:10.1126/science.1063814 · Cited by 314
PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS
Lehmann, J. (1946) · The Lancet · doi:10.1016/s0140-6736(46)91185-3 · Cited by 295
Yang, C., Luò, T., Shen, X., Wu, J., Gan, M., Xu, P., Wu, Z., Lin, S., Tian, J., Liu, Q., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30418-2 · Cited by 291
Vilchèze, C., & Jacobs JR., W. R. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0014-2013 · Cited by 289
ethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T., & Cooksey, R. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3799-3805.2003 · Cited by 288
Nikaido, H., & Thanassi, D. G. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1393 · Cited by 280
Pym, A. S., Saint-Joanis, B., & Cole, S. T. (2002) · Infection and Immunity · doi:10.1128/iai.70.9.4955-4960.2002 · Cited by 278
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness
Cohen, T., & Murray, M. (2004) · Nature Medicine · doi:10.1038/nm1110 · Cited by 277
Cohen, K. A., Abeel, T., Manson McGuire, A., Desjardins, C. A., Munsamy, V., Shea, T. P., Walker, B. J., Bantubani, N., Almeida, D. V., Alvarado, L., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001880 · Cited by 274
Maus, C. E., Plikaytis, B. B., & Shinnick, T. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3192-3197.2005 · Cited by 273
Maruri, F., Sterling, T. R., Kaiga, A. W., Blackman, A., van der Heijden, Y. F., Mayer, C., Cambau, E., & Aubry, A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr566 · Cited by 264
A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance
Louw, G. E., Warren, R. M., Gey van Pittius, N. C., McEvoy, C. R. E., Van Helden, P. D., & Victor, T. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01577-08 · Cited by 263
Streptomycin Resistance in Pulmonary Tuberculosis
Crofton, J., & Mitchison, D. A. (1948) · BMJ · doi:10.1136/bmj.2.4588.1009 · Cited by 261
Manca, C., Paul, S., Barry, C. E., Freedman, V. H., & Kaplan, G. (1999) · Infection and Immunity · doi:10.1128/iai.67.1.74-79.1999 · Cited by 254
Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis
Billington, O. J., McHugh, T. D., & Gillespie, S. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1866 · Cited by 251
Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015
Zhang, Y., & Yew, W.-W. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.15.0389 · Cited by 251
Antibiotic resistance mechanisms in M. tuberculosis: an update
Nguyen, L. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1727-6 · Cited by 249
Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis
Mariam, D. H., Mengistu, Y., Hoffner, S. E., & Andersson, D. I. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1289-1294.2004 · Cited by 247
Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis
Gagneux, S., Burgos, M. V., DeRiemer, K., Enciso, A., Muñoz, S., Hopewell, P. C., Small, P. M., & Pym, A. S. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020061 · Cited by 230
Self-citationMutation of tlyA Confers Capreomycin Resistance in Mycobacterium tuberculosis
Maus, C. E., Plikaytis, B. B., & Shinnick, T. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.571-577.2005 · Cited by 228
Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., Veigas, B., Amaral, L., & Viveiros, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034538 · Cited by 226
Irreversible Inhibition of the Mycobacterium tuberculosis β-Lactamase by Clavulanate
Hugonnet, J.-E., & Blanchard, J. S. (2007) · Biochemistry · doi:10.1021/bi701506h · Cited by 220
de Vos, M., Müller, B., Borrell, S., Black, P. A., van Helden, P. D., Warren, R. M., Gagneux, S., & Victor, T. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-12 · Cited by 219
Self-citationMahmoudi, A. (1993) · JAMA · doi:10.1001/jama.270.1.65 · Cited by 219
Some Observations on the Pathogenicity of Isoniazid-Resistant Variants of Tubercle Bacilli
Middlebrook, G., & Cohn, M. L. (1953) · Science · doi:10.1126/science.118.3063.297 · Cited by 217
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
Kaufmann, S. H. E., Lange, C., Rao, M., Balaji, K. N., Lotze, M., Schito, M., Zumla, A. I., & Maeurer, M. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70033-5 · Cited by 217
Blower, S. M., & Chou, T. (2004) · Nature Medicine · doi:10.1038/nm1102 · Cited by 216
Huitric, E., Verhasselt, P., Koul, A., Andries, K., Hoffner, S., & Andersson, D. I. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-09 · Cited by 215
Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis
Alangaden, G. J., Kreiswirth, B. N., Aouad, A., Khetarpal, M., Igno, F. R., Moghazeh, S. L., Manavathu, E. K., & Lerner, S. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1295 · Cited by 214
Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations
Sander, P., Springer, B., Prammananan, T., Sturmfels, A., Kappler, M., Pletschette, M., & Böttger, E. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1204-1211.2002 · Cited by 213
Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis: Table 1
da Silva, P. E. A., Von Groll, A., Martin, A., & Palomino, J. C. (2011) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2011.00831.x · Cited by 199
Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?
Chambers, H. F., Moreau, D., Yajko, D., Miick, C., Wagner, C., Hackbarth, C., Kocagöz, S., Rosenberg, E., Hadley, W. K., & Nikaido, H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2620 · Cited by 197
Schmalstieg, A. M., Srivastava, S., Belkaya, S., Deshpande, D., Meek, C., Leff, R., van Oers, N. S. C., & Gumbo, T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05546-11 · Cited by 195
Molecular Biology of Drug Resistance in Mycobacterium tuberculosis
Smith, T., Wolff, K. A., & Nguyen, L. (2012) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2012_279 · Cited by 190
Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain
Eldholm, V., Monteserin, J., Rieux, A., Lopez, B., Sobkowiak, B., Ritacco, V., & Balloux, F. (2015) · Nature Communications · doi:10.1038/ncomms8119 · Cited by 188
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux system
Milano, A., Pasca, M. R., Provvedi, R., Lucarelli, A. P., Manina, G., Luisa de Jesus Lopes Ribeiro, A., Manganelli, R., & Riccardi, G. (2009) · Tuberculosis · doi:10.1016/j.tube.2008.08.003 · Cited by 181
Microevolution of extensively drug-resistant tuberculosis in Russia
Casali, N., Nikolayevskyy, V., Balabanova, Y., Ignatyeva, O., Kontsevaya, I., Harris, S. R., Bentley, S. D., Parkhill, J., Nejentsev, S., Hoffner, S. E., et al. (2012) · Genome Research · doi:10.1101/gr.128678.111 · Cited by 181
Eldholm, V., Norheim, G., von der Lippe, B., Kinander, W., Dahle, U. R., Caugant, D. A., Mannsåker, T., Mengshoel, A. T., Dyrhol-Riise, A. M., & Balloux, F. (2014) · Genome Biology · doi:10.1186/s13059-014-0490-3 · Cited by 181
Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy
Pule, C. M., Sampson, S. L., Warren, R. M., Black, P. A., van Helden, P. D., Victor, T. C., & Louw, G. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv316 · Cited by 173
Desjardins, C. A., Cohen, K. A., Munsamy, V., Abeel, T., Maharaj, K., Walker, B. J., Shea, T. P., Almeida, D. V., Manson, A. L., Salazar, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3548 · Cited by 171
Malik, S., Willby, M., Sikes, D., Tsodikov, O. V., & Posey, J. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039754 · Cited by 170
Reiling, N., Homolka, S., Walter, K., Brandenburg, J., Niwinski, L., Ernst, M., Herzmann, C., Lange, C., Diel, R., Ehlers, S., et al. (2013) · mBio · doi:10.1128/mbio.00250-13 · Cited by 170
Gupta, A. K., Katoch, V. M., Chauhan, D. S., Sharma, R., Singh, M., Venkatesan, K., & Sharma, V. D. (2009) · Microbial Drug Resistance · doi:10.1089/mdr.2009.0054 · Cited by 168
Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., McEvoy, C. R. E., Grobbelaar, M., Murray, M., van Helden, P. D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1924oc · Cited by 166
Early clearance of M ycobacterium tuberculosis : a new frontier in prevention
Verrall, A. J., Netea, M. G., Alisjahbana, B., Hill, P. C., & van Crevel, R. (2013) · Immunology · doi:10.1111/imm.12223 · Cited by 164
Does M. tuberculosis genomic diversity explain disease diversity?
Coscolla, M., & Gagneux, S. (2010) · Drug Discovery Today: Disease Mechanisms · doi:10.1016/j.ddmec.2010.09.004 · Cited by 163
Self-citationNair, J., Rouse, D. A., Bai, G., & Morris, S. L. (1993) · Molecular Microbiology · doi:10.1111/j.1365-2958.1993.tb00924.x · Cited by 163
Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium tuberculosis Complex
Buriánková, K., Doucet‐Populaire, F., Dorson, O., Gondran, A., Ghnassia, J. C., Weiser, J., & Pernodet, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.143-150.2004 · Cited by 162
Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis
McGrath, M., Gey van Pittius, N. C., van Helden, P. D., Warren, R. M., & Warner, D. F. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt364 · Cited by 161
De Lorenzo, S., Alffenaar, J. W., Sotgiu, G., Centis, R., D'Ambrosio, L., Tiberi, S., Bolhuis, M. S., van Altena, R., Viggiani, P., Piana, A., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00124312 · Cited by 160
Lamichhane, G., Tyagi, S. K., & Bishai, W. R. (2005) · Infection and Immunity · doi:10.1128/iai.73.4.2533-2540.2005 · Cited by 158
Wang, F., Cassidy, C., & Sacchettini, J. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00320-06 · Cited by 154
The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis
Luciani, F., Sisson, S. A., Jiang, H., Francis, A. R., & Tanaka, M. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902437106 · Cited by 152
Will tuberculosis become resistant to all antibiotics?
Dye, C., & Espinal, M. (2001) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2000.1328 · Cited by 148
Koch, A. S., Mizrahi, V., & Warner, D. F. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.17 · Cited by 147
Hatherell, H.-A., Colijn, C., Stagg, H. R., Jackson, C., Winter, J. R., & Abubakar, I. I. (2016) · BMC Medicine · doi:10.1186/s12916-016-0566-x · Cited by 146
Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance
Moreno-Gámez, S., Hill, A. L., Rosenbloom, D. I. S., Petrov, D. A., Nowak, M. A., & Pennings, P. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424184112 · Cited by 145
Merker, M., Kohl, T. A., Roetzer, A., Trübe, L., Richter, E., Rüsch–Gerdes, S., Fattorini, L., Oggioni, M. R., Cox, H. S., Varaine, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082551 · Cited by 144
Heym, B., Stavropoulos, E., Honoré, N., Domenech, P., Saint‐Joanis, B., Wilson, T. M., Collins, D. M., Colston, M. J., & Cole, S. T. (1997) · Infection and Immunity · doi:10.1128/iai.65.4.1395-1401.1997 · Cited by 144
Haver, H. L., Chua, A. C. Y., Ghode, P. B., Lakshminarayana, S. B., Singhal, A., Mathema, B., Wintjens, R. T., & Bifani, P. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-15 · Cited by 144
Calver, A. D., Falmer, A. A., Murray, M. B., Strauss, O. J., Streicher, E. M., Hanekom, M., Liversage, T., Masibi, M., van Helden, P. D., Warren, R. M., et al. (2010) · Emerging infectious diseases · doi:10.3201/eid1602.090968 · Cited by 143
Coleman, M. T., Chen, R. Y., Lee, M., Lin, P. L., Dodd, L. E., Maiello, P. A., Via, L. E., Kim, Y., Marriner, G. A., Dartois, V. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009500 · Cited by 142
Lieberman, T. D., Wilson, D., Misra, R., Xiong, L. L., Moodley, P., Cohen, T., & Kishony, R. (2016) · Nature Medicine · doi:10.1038/nm.4205 · Cited by 142
Efflux Pump Gene Expression in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates
Li, G., Zhang, J., Guo, Q., Jiang, Y., Wei, J., Zhao, L., Zhao, X., Lu, J., & Wan, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119013 · Cited by 140
Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis
Borrell, S., & Gagneux, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03556.x · Cited by 140
Self-citationThe Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance
Sarathy, J. P., Dartois, V. A., & Lee, E. J. D. (2012) · Pharmaceuticals · doi:10.3390/ph5111210 · Cited by 138
Fitness of antibiotic-resistant microorganisms and compensatory mutations
Böttger, E. C., Springer, B., Pletschette, M., & Sander, P. (1998) · Nature Medicine · doi:10.1038/3906 · Cited by 138
China Tuberculosis Control Collaboration (1996) · The Lancet · doi:10.1016/s0140-6736(96)90537-1 · Cited by 138
An outer membrane channel protein of Mycobacterium tuberculosis with exotoxin activity
Danilchanka, O., Sun, J., Pavlenok, M., Maueröder, C., Speer, A., Siroy, A., Marrero, J., Trujillo, C., Mayhew, D. L., Doornbos, K. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400136111 · Cited by 135
Comparative genomics of microbial drug efflux systems.
Paulsen, I. T., Chen, J. W., Nelson, W. C., & Saier, M. H. (2001) · PubMed · Cited by 132
Werngren, J., & Hoffner, S. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1520-1524.2003 · Cited by 126
Borrell, S., Teo, Y., Giardina, F., Streicher, E. M., Klopper, M., Feldmann, J., Müller, B., Victor, T. C., & Gagneux, S. (2013) · Evolution Medicine and Public Health · doi:10.1093/emph/eot003 · Cited by 125
Self-citationTowards host-directed therapies for tuberculosis
Zumla, A. I., Chakaya, J. M., Höelscher, M., Ntoumi, F., Rustomjee, R., Vilaplana, C., Yeboah‐Manu, D., Rasolofo, V., Munderi, P., Singh, N., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4696 · Cited by 125
Self-citationEffect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis
Fenner, L., Egger, M., Bodmer, T., Altpeter, E., Zwahlen, M., Jaton, K., Pfyffer, G. E., Borrell, S., Dubuis, O., Bruderer, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06460-11 · Cited by 124
Self-citationMailaender, C., Reiling, N., Engelhardt, H., Bossmann, S. H., Ehlers, S., & Niederweis, M. (2004) · Microbiology · doi:10.1099/mic.0.26902-0 · Cited by 120
Minato, Y., Thiede, J. M., Kordus, S. L., McKlveen, E. J., Turman, B. J., & Baughn, A. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00647-15 · Cited by 119
André, E., Goeminne, L., Cabibbe, A. M., Beckert, P., Kabamba, B., Mathys, V., Gagneux, S., Niemann, S., van Ingen, J., & Cambau, E. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.006 · Cited by 118
Self-citationPayen, M. C., Wit, S. D., Martin, C., SERGYSELS, R., Muylle, I., Laethem, Y. V., & Clumeck, N. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0414 · Cited by 116
Beckert, P., Hillemann, D., Kohl, T. A., Kalinowski, J., Richter, E., Niemann, S., & Feuerriegel, S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06227-11 · Cited by 116
Niemann, S., Diel, R., Khechinashvili, G., Gegia, M., Mdivani, N., & Tang, Y. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00715-10 · Cited by 115
Visualization of mycobacterial membrane dynamics in live cells
Rodriguez‐Rivera, F. P., Zhou, X., Theriot, J. A., & Bertozzi, C. R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12541 · Cited by 114
N -methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis
Warrier, T., Kapilashrami, K., Argyrou, A., Ioerger, T. R., Little, D., Murphy, K. C., Nandakumar, M., Park, S., Gold, B. S., Mi, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606590113 · Cited by 111
Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates
Gillespie, S. H., Basu, S., Dickens, A. L., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki191 · Cited by 108
Drug Susceptibility ofMycobacterium tuberculosisBeijing Genotype and Association with MDR TB
de Steenwinkel, J. E. M., ten Kate, M. T., de Knegt, G. J., Kremer, K., Aarnoutse, R. E., Boeree, M. J., Verbrugh, H. A., van Soolingen, D., & Bakker‐Woudenberg, I. A. J. M. (2012) · Emerging infectious diseases · doi:10.3201/eid1804.110912 · Cited by 106
Song, T., Park, Y., Shamputa, I. C., Seo, S.-H., Lee, S. Y., Jeon, H.-S., Choi, H., Lee, M., Glynne, R. J., Barnes, S. W., et al. (2014) · Molecular Microbiology · doi:10.1111/mmi.12520 · Cited by 100
Liu, J., & Nikaido, H. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.7.4011 · Cited by 98
Bergval, I., Schuitema, A. R. J., Klatser, P. R., & Anthony, R. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp237 · Cited by 97
Luò, T., Yang, C., Peng, Y., Lu, L., Sun, G., Wu, J., Jin, X., Hong, J., Li, F., Mei, J., et al. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.04.005 · Cited by 90
Welin, A., Raffetseder, J., Eklund, D., Stendahl, O. I., & Lerm, M. (2011) · Journal of Innate Immunity · doi:10.1159/000325297 · Cited by 90
Nguyen, L., & Pieters, J. (2009) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061008-103123 · Cited by 90
Zhao, F., Wang, X.-D., Erber, L. N., Luo, M., Guo, A.-Z., Yang, S.-S., Gu, J., Turman, B. J., Gao, Y.-R., Li, D., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01775-13 · Cited by 87
Mestre, O., Luò, T., Vultos, T. D., Kremer, K., Murray, A., Namouchi, A., Jackson, C., Rauzier, J., Bifani, P. J., Warren, R. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016020 · Cited by 85
Rock, J. M., Lang, U. F., Chase, M. R., Ford, C. B., Gerrick, E. R., Gawande, R., Coscollá, M., Gagneux, S., Fortune, S. M., & Lamers, M. H. (2015) · Nature Genetics · doi:10.1038/ng.3269 · Cited by 82
Self-citationElucidating population-wide mycobacterial replication dynamics at the single-cell level
Mouton, J., Hélaine, S., Holden, D. W., & Sampson, S. L. (2016) · Microbiology · doi:10.1099/mic.0.000288 · Cited by 81
Tuberculosis: drug resistance, fitness, and strategies for global control
Böttger, E. C., & Springer, B. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0606-9 · Cited by 80
Post, F. A., Willcox, P. A., Mathema, B., Steyn, L. M., Shean, K., Ramaswamy, S. V., Graviss, E. A., Shashkina, E., Kreiswirth, B. N., & Kaplan, G. (2004) · The Journal of Infectious Diseases · doi:10.1086/421501 · Cited by 80
Chapman, P. F. (1934) · BMJ · doi:10.1136/bmj.2.3857.1073-b · Cited by 78
Gene Loss Dominates As a Source of Genetic Variation within Clonal Pathogenic Bacterial Species
Bolotin, E., & Hershberg, R. (2015) · Genome Biology and Evolution · doi:10.1093/gbe/evv135 · Cited by 76
Role of pharmacogenomics in the treatment of tuberculosis: a review
Swaminathan, S., & Ramachandran, G. (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s15454 · Cited by 75
The trade-off between rate and yield in the design of microbial metabolism
Frank, S. A. (2010) · Journal of Evolutionary Biology · doi:10.1111/j.1420-9101.2010.01930.x · Cited by 67
van Doorn, H. R., de Haas, P. E. W., Kremer, K., Vandenbroucke‐Grauls, C. M. J. E., Borgdorff, M. W., & van Soolingen, D. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01495.x · Cited by 66
Qi, Q., Preston, G. M., & MacLean, R. C. (2014) · mBio · doi:10.1128/mbio.01562-14 · Cited by 66
Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes
Houghton, J. L., Green, K. D., Pricer, R. E., Mayhoub, A. S., & Garneau‐Tsodikova, S. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks497 · Cited by 65
Meftahi, N., Namouchi, A., Mhenni, B., Brandis, G., Hughes, D., & Mardassi, H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv345 · Cited by 53
Danilchanka, O., Pires, D., Anes, E., & Niederweis, M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04222-14 · Cited by 52
Müller, B., Chihota, V. N., Pillay, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070919 · Cited by 52
Gavello, D., Rojo‐Ruiz, J., Marcantoni, A., Franchino, C., Carbone, E., & Carabelli, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041530 · Cited by 51
Costs of antibiotic resistance – separating trait effects and selective effects
Hall, A. R., Angst, D. C., Schiessl, K. T., & Ackermann, M. (2014) · Evolutionary Applications · doi:10.1111/eva.12187 · Cited by 49
Cohen, K. A., El‐Hay, T., Wyres, K. L., Weissbrod, O., Munsamy, V., Yanover, C., Aharonov, R., Shaham, O., Conway, T., Goldschmidt, Y., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.041 · Cited by 49
Barnett, M., BUSBY, S. R., & Mitchison, D. A. (1953) · PubMed · Cited by 48
Capreomycin susceptibility is increased by TlyA‐directed 2′‐O‐methylation on both ribosomal subunits
Monshupanee, T., Johansen, S. K., Dahĺberg, A. E., & Douthwaite, S. R. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08168.x · Cited by 48
Knight, G. M., Colijn, C., Shrestha, S., Fofana, M. O., Cobelens, F. G. J., White, R. G., Dowdy, D. W., & Cohen, T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ579 · Cited by 48
Lanzas, F., Karakousis, P. C., Sacchettini, J. C., & Ioerger, T. R. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01122-13 · Cited by 47
Bergval, I., Kwok, B., Schuitema, A. R. J., Kremer, K., van Soolingen, D., Klatser, P. R., & Anthony, R. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029108 · Cited by 47
David, S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.391 · Cited by 46
Warrier, T., Martínez-Hoyos, M., Amieva, M. M., Colmenarejo, G., de Francisco, E. P., Álvarez-Pedraglio, A. I., Fraile-Gabaldón, M. T., Torres, P. A., Quezada, L. A. L., Gold, B. S., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00025 · Cited by 44
Biological cost in Mycobacterium tuberculosis with mutations in the rpsL, rrs, rpoB, and katG genes
Spies, F. S., von Groll, A., Ribeiro, A., Ramos, D. F., Ribeiro, M. O., Costa, E. R. D., Martin, A., Palomino, J. C., Rossetti, M. L. R., Zaha, A., et al. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.11.004 · Cited by 43
Salvatore, P. P., Becerra, M. C., Wiesch, P. A. Z., Hinkley, T., Kaur, D., Sloutsky, A., & Cohen, T. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv347 · Cited by 38
Rifampicin Resistance: Fitness Costs and the Significance of Compensatory Evolution
Hughes, D., & Brandis, G. (2013) · Antibiotics · doi:10.3390/antibiotics2020206 · Cited by 37
Rabello, M. C. D. S., Matsumoto, C. K., de Almeida, L. G. P., Menendez, M. C., de Oliveira, R. S., Silva, R. M., García, M. J. G., & Leão, S. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029884 · Cited by 33
Contribution of β‐lactamase production to the resistance of mycobacteria to β‐lactam antibiotics
Quinting, B., Reyrat, J., Monnaie, D., Amicosante, G., Pelicic, V., Gicquel, B., Frère, J., & Galleni, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00286-x · Cited by 26
Naidoo, C., & Pillay, M. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12415 · Cited by 24
Janardhan, S., Vivek, M. R., & Sastry, G. N. (2016) · Molecular BioSystems · doi:10.1039/c6mb00457a · Cited by 24
Cited by
Ecology and evolution of Mycobacterium tuberculosis
Gagneux, S. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2018.8 · Cited by 599
Self-citationSequencing-based methods and resources to study antimicrobial resistance
Boolchandani, M., D’Souza, A. W., & Dantas, G. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0108-4 · Cited by 522
Shamsudin, N. F., Ahmed, Q. U., Mahmood, S., Ali Shah, S. A., Khatib, A., Mukhtar, S., Alsharif, M. A., Parveen, H., & Zakaria, Z. A. (2022) · Molecules · doi:10.3390/molecules27041149 · Cited by 508
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Metadata
- Authors
- Gygli, S. M., Borrell, S., Trauner, A., & Gagneux, S.
- Venue
- FEMS Microbiology Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-03-25
- Volume
- 41
- Issue
- 3
- Pages
- 354-373
- ISSN
- 0168-6445 (ISSN-L)
- 1574-6976
- OpenAlex
- W2599698180
- Cited by
- 457
- References
- 180
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.